All In Biotech

Drug Trial Radar · NCT03486301

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

87

Actual

Start

Feb 15, 2018

Primary completion

Mar 31, 2024

Study completion Apr 30, 2024

Sponsor

Lead sponsor
Eikon TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Apr 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Conditions

  • Tumor, Solid

Interventions

  • BDB001 (EIK1001)Drug

    BDB001 (EIK1001) is an immunotherapy agent.

  • PembrolizumabDrug

    Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability: incidence of adverse events and any dose limiting toxicityTime frame: Up to 30 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Florida Cancer Specialists

    Sarasota, Florida

  • Atlantic Health

    Morristown, New Jersey

  • Tennessee Oncology

    Nashville, Tennessee

  • NEXT Oncology

    San Antonio, Texas

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.